ERGIC-53L Activators
ERGIC-53L Activators encompass a spectrum of chemical compounds that indirectly promote the functional activity of ERGIC-53L through a variety of intracellular mechanisms impacting glycoprotein processing and trafficking. Calcium ionophore A23187 and Thapsigargin, by increasing intracellular calcium levels, directly enhance the lectin activity of ERGIC-53L, pivotal for binding glycoproteins in the ER-Golgi intermediate compartment. Similarly, Brefeldin A disrupts Golgi structure, which could lead to an upsurge in the functional demand for ERGIC-53L in glycoprotein sorting. Ionophores such as Nigericin and Monensin alter ion gradients, indirectly necessitating greater ERGIC-53L activity to maintain glycoprotein processing within the altered ionic milieu of the Golgi. Meanwhile, inhibitors of glycoprotein processing enzymes, like Swainsonine, Castanospermine, Deoxynojirimycin,and Kifunensine, cause an accumulation of glycoproteins in the ER, thereby potentially augmenting the need for ERGIC-53L's role in their proper trafficking. This is essential since ERGIC-53L is crucial in the quality control and movement of glycoproteins from the ER to the Golgi apparatus.
Moreover, compounds such as Bafilomycin A1, FCCP, and Nocodazole disrupt various aspects of intracellular trafficking and organelle function, which may indirectly enhance the importance of ERGIC-53L in the cellular logistics of glycoprotein handling. Bafilomycin A1, by inhibiting V-ATPase, affects endosomal acidification and could thereby increase reliance on ERGIC-53L for bypassing compromised trafficking routes. FCCP's action in dissipating proton gradients can impact organelle function, possibly leading to increased ERGIC-53L activity to counterbalance disrupted glycoprotein transport. Lastly, Nocodazole's disruption of microtubules may lead to a greater dependence on ERGIC-53L function for the intracellular transport of glycoproteins, highlighting the adaptability of ERGIC-53L in response to cellular stressors that impinge on its primary function in glycoprotein trafficking.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Calcium ionophore A23187 increases intracellular calcium levels, which is essential for the proper folding and function of ERGIC-53L as it is a calcium-dependent lectin. Elevated calcium can enhance ERGIC-53L's ability to bind to glycoproteins in the ER-Golgi intermediate compartment. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels. This rise in calcium concentration can indirectly enhance ERGIC-53L activity by promoting its glycoprotein binding function in the secretory pathway. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which can lead to an accumulation of proteins in the ERGIC, potentially increasing the functional load and necessity for ERGIC-53L in glycoprotein trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering cation exchange. This disruption can indirectly necessitate increased ERGIC-53L function, as it may help to maintain glycoprotein processing under altered ionic conditions. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine inhibits mannosidase II, which can lead to the accumulation of misfolded glycoproteins in the ER. This may indirectly increase the demand for ERGIC-53L function in glycoprotein quality control and trafficking. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine is an inhibitor of glucosidase I and II, enzymes involved in glycoprotein processing. Inhibition of these enzymes could lead to an increased functional requirement for ERGIC-53L in the trafficking of glycoproteins. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
Deoxynojirimycin is another glucosidase inhibitor that could amplify the functional role of ERGIC-53L by causing the accumulation of glycoproteins requiring processing and trafficking, indirectly enhancing the protein’s activity. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that leads to the accumulation of high-mannose glycans, which may increase the requirement for ERGIC-53L's role in trafficking and processing these glycoproteins. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a V-ATPase inhibitor that disrupts endosomal acidification and can affect the trafficking of glycoproteins. This may enhance the role of ERGIC-53L in compensating for impaired trafficking routes. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $92.00 $348.00 | 46 | |
FCCP dissipates proton gradients across membranes, potentially affecting organelle functions and could enhance the role of ERGIC-53L in maintaining glycoprotein trafficking under these conditions. | ||||||